Parkwood LLC Janux Therapeutics, Inc. Transaction History

Parkwood LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$11.1 - $18.26 $131,901 - $216,983	-11,883 Reduced 35.63%	21,469 $283,000
Q3 2022 Nov 14, 2022	SELL	$10.82 - $16.84 $4,306 - $6,702	-398 Reduced 1.18%	33,352 $452,000
Q2 2022 Aug 15, 2022	BUY	$9.52 - $15.65 $52,283 - $85,949	5,492 Added 19.44%	33,750 $34,000
Q1 2022 May 13, 2022	SELL	$13.24 - $20.24 $51,238 - $78,328	-3,870 Reduced 12.05%	28,258 $405,000
Q4 2021 Feb 11, 2022	BUY	$15.44 - $27.32 $175,259 - $310,109	11,351 Added 54.63%	32,128 $634,000

Q3 2021 Nov 12, 2021	BUY	$20.7 - $34.69 $430,083 - $720,754	20,777 New	20,777 $449,000

123

25.3M

92K

161K

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $1.75B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

Get notified when there are updates to the investment portfolio of Parkwood LLC, based on Form 13F filings with the SEC.

Stay updated on Parkwood LLC with notifications on news.